Kairos Pharma, LTD. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2023 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Kairos Pharma, LTD. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2023 to Q4 2024.
  • Kairos Pharma, LTD. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2024 was $841K, a 46.8% decline year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2024 $841K -$740K -46.8% Dec 31, 2024 10-K 2025-04-15
Q4 2023 $1.58M Dec 31, 2023 10-K 2025-04-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.